A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Rigosertib (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Onconova Therapeutics
- 11 Oct 2017 Planned End Date changed from 1 May 2018 to 1 Jul 2018.
- 11 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.
- 28 Jul 2017 Planned End Date changed from 1 Dec 2017 to 1 May 2018.